which may manifest with an abrupt onset, reflecting severe venous hypertension 3, 6, 27 . Treatment options for high-flow CCF consist in endovascular obliteration by means of detachableballoons16 or coils10 and, less frequently, direct surgical repair 27 . Covered stents have been proposed recently as an alternative technique to obtain occlusion of CCF 8, 14, 23 .
Introduction
A covered stent was successfully implanted to treat a direct carotid-cavernous fistula (CCF) in a 63-year-old woman. This procedure was undertaken following failure to obliterate the fistula by means of a detachable balloon due to carotid artery laceration. Immediate and six month control angiograms demonstrated complete occlusion of the fistula and normal lumen diameter of the cavernous carotid artery.
A carotid-cavernous fistula usually follows rupture of a cavernous sinus carotid aneurysm or may result from post-traumatic or iatrogenic injury to the artery [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Bruit, chemosis, exophthalmus, partial or complete ophthalmoplegia and headache are common clinical findings, Covered Stent Implantation for the Treatment of Direct Carotid-Cavernous Fistula and Its Mid-Term Follow-up 186 mal veins afferent to the cavernous sinus. The mesh of coils within the CS should present, in case of large communications, an interface to the parent vessel, like an endovascular occlusion of intracranial aneurysms, with the risk of clot formation and acute thromboembolic complications that can be reduced with heparinization and antiplatelet therapy.
Halbach et Al 1, 4, 5, 7, [11] [12] [13] [17] [18] [19] [20] [21] [22] 25 described some failures of the platinum coil procedure in CCFs. In one case, finally treated with endovascular trapping of the ICA, the cast of platinum coils previously released into the CS projected through the fistula into the parent artery. In a second case closure of anterior drainage was achieved, but complicated by distal migration of platinum coils with aggravation of ocular symptoms. Endovascular cavernous sinus embolization with balloons or coils may be responsible for cranial nerve palsy. In 1999 Sencer et Al 24 reported a case with mechanical compression of the lateral rectus muscle by balloons. These difficulties could be resolved by an intracranial covered stent. In 2001 Weber et Al 28 described a case of direct carotid cavernous fistula cured by endovascular porous coronary stent. This kind of device is highly flexible and easily follows the curves of vessels.
In 2002 Kocer er Al 14 reported a case of iatrogenic carotid cavernous fistula successfully treated with endovascular stent-graft (Jostent 12 x 4 mm). Covered stent or stent-graft provides waterproof sealing of the bridged vessel segment. Stent-graft has a cover of polytetrafluoroethylene (PTFE), used for many years as a graft material during vascular surgery. The stent-graft has a low incidence of complications, including acute stent thrombosis. Use of this device is the therapy of choice for acute coronary rupture. Jostent, provided by Jomed, barely follows the curves of intracranial vessels.
It can be used to reach only the first segment of intracranial ICA, the intracavernous segment. This poor navigability is closely connected to the length of the device.
In recent years, the use of covered stents has become a promising alternative to other endovascular techniques and it has been suggested that covered stents may be an efficient way to occlude a fistula preserving the parent artery.
In 2007 Gomez et Al 9 presented their experience using balloon-expandable covered stents to treat CCF, focusing on arterial wall reconstruction. It was the first series with midterm followup between three months and 3.5 years. Seven post-traumatic direct CCF were treated using polytetrafluoroethylene (PTFE)-covered stents between April 2003 and September 2006. Five were treated with covered stents alone. One patient with transection of the internal carotid artery (ICA) first underwent bare stent placement to provide support for the covered stent. One patient had to be treated with coils and n-BCA. Control angiograms obtained in the seven patients demonstrated occlusion of the fistula and preservation of the ICA in all cases. There was no mortality and no immediate postprocedural morbidity. The authors described PTFEcovered stents as a promising intracranial therapeutic alternative to treat CCF to preserve the parent artery by reconstructing the arterial wall.
In the same year, Archondakis et Al 2 treated eight patients with post-traumatic CCF by positioning a covered stent in the intracranial internal carotid artery (ICA). They received periodic clinical and angiographic follow-up to evaluate the patency and the stability of clinical results. In all cases, the symptoms related to the CCF regressed after treatment and did not recur in the follow-up. Two patients presented residual filling of the CCF at the end of the procedure. The angiographic follow-up revealed a good patency of the ICA in six out of seven patients. One patient presented an ICA asymptomatic occlusion. One patient required transvenous coil occlusion of the cavernous sinus. The search strategy was principally based on article references read on the web or in scientific journals, after a complete analysis and review of all national and international literature on CCF treatment.
Analysis
Although the therapeutic goal is the occlusion of the fistula with preservation of the ICA, in case of failure of a preservative procedure or further difficulties during an endovascular treatment, trapping must be considered. Therefore previous balloon test occlusion must be always performed. The use of stents for management of this type of intracranial arterial disease has been limited by the interventionalist's inability to negotiate the relatively stiff covered stent with the balloon assembly through the tortuous intracranial vessels such as the carotid artery system without damaging the vessel in the process.
There are few reports in the literature on the long-term follow-up of treatment of CCF with a stent-graft. When a traditional endovascular procedure cannot be performed, the stent-graft could be used before trapping, always after balloon test occlusion. We expect a positive outcome from the initial experiences. Future technical developments of this device will overcome some of the current limitations, responsible for our failure 2, 9, 15 .
Illustrative case report
In September 2004, a 63-year-old woman presented to an outside facility with a soft pulsatile mass in the right orbitozygomatic region and complaints of right double vision, progressively established a few days prior to admission. The patient had undergone surgical reduction of right zygomatic and maxillar fractures three weeks before, following craniofacial trauma due to a motor vehicle accident. Physical and neurological examination revealed right eye pulsatile proptosis associated with ipsilateral complete right ophthalmoplegia without mydriasis. Magnetic resonance angiography (MRA) disclosed a right carotid-cavernous fistula.
The patient was then referred to our department for treatment (Figure 1) . The patient underwent a four-vessel cerebral angiography and right vertebral artery injection during compression of the ipsilateral ICA. The angiograms demonstrated a carotid-cavernous fistula with retrograde flow in the superior and inferior ophthalmic veins. Following a bolus of 5000 I.U. of heparin and 1000 mg of acetylsalicylate, a de- tachable balloon device (Goldbal 1, Balt) was placed within the fistula by the transarterial route. However, angiographic control following balloon inflation showed persistence of the fistula due to carotid artery laceration. A covered stent (Jostent Graftmaster 4 mm x 19 mm, Jomed) was then advanced into the right internal carotid artery and inflated in the cavernous carotid siphon, covering the dissecting arterial segment and across the fistular orifice. Immediate control angiogram showed occlusion of the fistula (Figure 2 ). At the end of the procedure a load of 300 mg of clopidogrel was administered. The immediate post-procedure period was uneventful and the patient experienced regression of proptosis, while pulsation was absent. The right ophthalmoplegia persisted after the procedure. The patient was kept in a protocol of aspirin 300 mg and clopidogrel 75 mg daily for one month and aspirin 300 mg alone thereafter. Six months after the procedure, neurological examination revealed only a mild right sixth cranial nerve palsy. The first control angiogram (six months later) showed complete occlusion of the fistula and normal lumen diameter of the internal carotid artery. The last angiogram (October 2007), three years after the endovascular procedure, shows persistence of the result achieved. 
Discussion
Optimal management of high-flow CCF consists in occlusion of the fistula with preservation of the internal carotid artery patency 16 . For this purpose, endovascular techniques have been used during recent decades for embolization of the fistula by means of balloons 16 or coils 10 . To date, endovascular placement of a detachable balloon device within the fistula by a transarterial route has been established as the gold standard procedure 3, 6, 16, 27 . Occasionally, transarterial obliteration of the fistula is achievable only by occlusion of the internal carotid artery, by means of multiple balloon devices. Alternatively, a transvenous balloon placement may be performed, usually by the inferior petrous sinus or superior ophthalmic vein route, particularly when the internal carotid artery appears too tortuous or severely stenotic 11, 16 . Failure of the detachable balloon technique may follow prolapse, migration, deflation or rupture of the device, resulting in carotid artery occlusion or distal thromboembolic episodes 16 . In such cases, direct surgical repair of the fistula may be attempted 27 . Late adverse events of endovascular treatment of CCF include formation of false aneurysm or fistula re-formation 17 . Covered stents have been successfully used in the management of aortic, coronary and peripheral vessel pathologies such as arteriovenous fistulas, aneurysms and ruptures 7, 19 . They originally had a sandwich-like design to fix a thin polytetrafluoroethylene (PTFE) membrane between two stainless stents. The PTFE membrane is a compatible polymer that can be manufactured in the form of distensible microporous membranes; it is the best available covering material for the stent grafts in terms of patency rates 20, 22 . Later, new self-expanding covered stents (made of Nitinol) arose and their design was refined to extend the membrane up to the stent edges because restenosis was noted to develop at the proximal and distal ends, which were not covered with the membrane 5 . In the neurovascular field, covered stents have been employed in the treatment of cervical 8, 18 and skull base 1,21 arterial dissections, pseudoaneurysms and fistulas, as an alternative to the combined use of uncovered devices and trans-stent coil embolization. Application of covered stents for intracranial neurovascular disease is a recently explored treatment option. Thus far, a few cases of intracranial aneurysms 8, 4, 13, 22, 25 and fistulas 8, 14, 23 treated by means of covered stent have been published in the literature. Overall, a successful direct obliteration of a CCF with implantation of a covered stent in the internal carotid artery has been reported in only five cases 8, 14 . The use of a covered stent for CCF management, compared with other endovascular materials, potentially carries several advantages, thus appearing an attractive alternative. Unlike balloons, there is no risk of rupture or deflation of the device, while the possibility of pseudoaneurysm formation is virtually eliminated 14, 25 . A covered stent provides ready fistula obliteration with preservation of the parent arterial lumen 8, 14 . Moreover, a lower risk of distal thromboembolic episodes is likely, at least in the early stages, compared to that associated with internal carotid artery sacrifice by means of balloon devices 14 . Ultimately, we feel that, from a theoretical standpoint, a covered stent offers a potentially permanent exclusion from the circulation of an arteriovenous fistula, preventing re-formation by a definitive reconstruction of the parent vessel walls. However, the mechanical properties of the currently available covered stents, in terms of longitudinal flexibility and section diameter, imply technical difficulties in their application. Advancement and navigation of the rigid covered stent, originally designed for coronary pathology, into the tortuous intracranial arterial tree may be inherently related to several risks as long as technically demanding maneuvers are required. Moreover, in cases of wide internal carotid arteries, there may be need of further stent expansion by means of angioplasty balloon 8 . Local vasospasm following irritation and direct vessel injury are the main concerns in that respect 8, 14, 22 . Nevertheless, as in our case, two recent series of 11 and 24 patients respectively, treated with covered stents for intracranial CCFs and aneurysms, found no evidence of vasospasm or vessel injury 8, 22 . Late stent thrombosis following intimal hyperplastic reaction is also a concern regarding the use of covered stents. Felber et Al 8 reported no late occlusions of the devices in nine patients treated by means of covered stents for extracranial and intracranial aneurysms and arteriovenous fistulas, with follow-up ranging from three months to five years. Similarly, in a series of 24 patients with intracranial aneurysms treated with endovascular deployment of covered stent, evidence of minimal intimal hyperplasia was observed in only one patient during a follow-up period of six to 24 months 22 . Yet, several measures may circumvent these limitations, such as injection of papaverine into the ICA during, and standard antiplatelet drug medication after procedure. Furthermore, case-to-case patient selection based on careful scrutiny of angiographic Pattern and appropriately designed devices suitable for intracranial use will be essential to rationalize indications and the optimize results of this promising endovascular technique. Although the worldwide experience of covered stent employment for the management of CCF is so far very limited, it appears to be an effective alternative, particularly in cases in which other traditional procedures have failed. Stent patency on a long-term basis and associated risk of late ischemic attacks following covered stent placement within the intracranial internal carotid artery are the issues to be determined in the future.
